Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Autophagy in MASLD: A Metabolic and Precision Medicine Perspective.
Clinical takeawayNo clinical action yet: mechanistic insights from genetic and preclinical studies. Consider future genetic testing or autophagy biomarkers if validated in humans.
What it foundGenetic variants (PNPLA3 p.I148M, ATG7 loss-of-function) impair autophagy and predispose to MASLD progression to ballooning, fibrosis, and HCC.
ContextConfirms autophagy's role in MASLD pathogenesis and introduces genetic modifiers as potential precision medicine targets, but human therapeutic applications remain unproven.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.
Decision at stakethe role of autophagy in MASLD progression and potential therapeutic targets
AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Cazzaniga A … Valenti L · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗